Jove
Visualize
Contact Us

Related Concept Videos

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Current And Evolving Biomarkers In The Diagnosis And Management Of Testicular Germ Cell Tumors.
  1. Home
  3. Current And Evolving Biomarkers In The Diagnosis And Management Of Testicular Germ Cell Tumors.

Related Experiment Video

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.8K

Current and Evolving Biomarkers in the Diagnosis and Management of Testicular Germ Cell Tumors.

Jennifer Sykes1, Alain Kaldany1, Thomas L Jang1,2

  • 1Division of Urology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.

Journal of Clinical Medicine
|December 17, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

New microRNA (miRNA) biomarkers show promise for improving testicular cancer diagnosis and management. miR371a-3p offers higher accuracy than traditional markers, aiding treatment decisions for early and advanced stages.

Keywords:
biomarkersgerm cell tumormicroRNAserum tumor markerstesticular cancer

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.5K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

10.9K

Related Experiment Videos

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.8K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.5K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

10.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Testicular cancer is the most common cancer in young men, with generally favorable outcomes.
  • Traditional serum tumor markers (STMs) like AFP, β-hCG, and LDH have limitations in sensitivity and specificity for diagnosis and monitoring.
  • Novel biomarkers are needed to improve risk stratification, surveillance, and response assessment in testicular germ cell tumors (GCTs).

Purpose of the Study:

  • To review the role of biomarkers in managing testicular cancer.
  • To highlight the potential of novel biomarkers, particularly microRNAs (miRNAs), in improving diagnostic accuracy and clinical decision-making.
  • To discuss the limitations of current markers and the ongoing investigation of emerging biomarkers like miR371a-3p, ctDNA, and CTCs.

Main Methods:

  • Literature review of traditional and novel biomarkers for testicular cancer.
  • Analysis of the performance characteristics of microRNA-371a-3p (miR371a-3p) in GCT patients.
  • Discussion of the potential clinical applications of miR371a-3p in treatment and surveillance decisions.

Main Results:

  • miR371a-3p demonstrates high sensitivity (90-92%) and specificity (84-86%) in GCT patients, outperforming traditional STMs.
  • This miRNA biomarker can potentially identify micrometastases in early-stage disease and residual viable GCT post-chemotherapy.
  • While promising, miR371a-3p has limitations, notably its inability to detect teratoma.

Conclusions:

  • miR371a-3p represents a significant advancement in testicular cancer biomarker research.
  • Further clinical trials are necessary to validate miR371a-3p and establish its role in routine clinical practice.
  • Emerging biomarkers like ctDNA and CTCs require further investigation for their utility in GCT management.